Biotech Buyouts Show Sector Not In A Bubble: StockTwits.com

NEW YORK (TheStreet) -- Big pharma buyouts have squashed talk of a biotech bubble. This morning, Forest Laboratories  (FRX) announced it would acquire Furiex Pharmaceuticals  (FURX) for about $1.1 billion, or $95 per share. Forest will pay an additional amount, up to $30 per share or $360 million, should Furiex's drug eluxadoline, a treatment for irritable bowel syndrome, receive broad approval.

The merger is the latest in a series of billion-plus biotech deals announced in the past few months. And investors on StockTwits.com say it confirms that biotech valuations were never that frothy, as many suggested when the sector sold-off last month.

$FURX Even if milestone achieved later and deal sweetened, still gets done below top tick. Goes to show bios were priced for perfection.

- JLL IV (@TXplunger) Apr. 28 at 08:42 AM

The Furiex acquisition comes a few months after Actavis  (ACT) announced it would acquire Forest Laboratories for $25 billion in equity and cash. At the time of the announcement, Actavis said that the combined company would have annual revenues of over $15 billion in 2015. Forest made it clear that its "blockbuster" gastrointestinal drugs were a major reason for the deal.

$ACT eats $FRX who eats $FURX #biotechfoodchain

- Kevin F. (@Katsu) Apr. 28 at 07:28 AM

The Furiex purchase also comes in the wake of Pfizer's  (PFE) pursuit of AstraZeneca  (AZN). Pfizer management said in a press release early this morning that it attempted to acquire AstraZeneca for $76.62-per-share in January. AstraZeneca declined the offer, saying it significantly undervalued its drug pipeline. Pfizer contacted AstraZeneca management on April 26 seeking to renew merger discussions.

If you liked this article you might like

Cramer: There Are Some Bargains Out There

Cramer: There Are Some Bargains Out There

Teva, Actavis, Other Generic Drugmakers May Be on Acquisition Trail

Jim Cramer -- Deal Activity in Specialty Pharma Reaches a Frenzied Pace

Why Endo International Can Deliver Solid Rewards With Minimal Risk

3 Stocks Driving The Health Care Sector Higher